Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 544.00
Bid: 538.00
Ask: 542.00
Change: 11.00 (2.06%)
Spread: 4.00 (0.743%)
Open: 530.00
High: 544.00
Low: 529.00
Prev. Close: 533.00
POLR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Team Acquisition Completion

19 Oct 2020 07:00

RNS Number : 3843C
Polar Capital Holdings PLC
19 October 2020
 

19 October 2020

 

Polar Capital Holdings plc completes the acquisition of International and World equity strategies

 

Polar Capital Holdings plc ("Polar Capital"), the specialist active asset management group, today announces the completion of the acquisition of the International Value and World Value equity team led by Pierre Py and Greg Herr ("the Managers") from the Los Angeles-based asset manager First Pacific Advisors, LP.

- A new joint venture, Phaeacian Partners LLC ("Phaeacian"), has been established

- Two 1940 Act mutual funds - the FPA Paramount Fund, Inc. and the FPA International Value Fund - have been reorganised into the Phaeacian Global Value Fund and the Phaeacian Accent International Value Fund

- Phaeacian assets under management at the transition total $545m (as at the end of September 2020)

The completion of the transaction provides the Managers and Polar Capital with the opportunity to build Phaeacian into a significant presence in the International (global ex-US) and Global equity sectors.

The Managers bring an exceptional performance record. Over five years to end September 2020, the FPA International Value Fund is five-star rated by Morningstar and the FPA Paramount Fund is four-star rated. Additionally, International Value is the top ranked fund in its Morningstar sector over three and five years and holds a Morningstar Bronze rating*. All performance track records and ratings have been ported across to Phaeacian.

The launch and establishment of Phaeacian is consistent with Polar Capital's strategy of diversifying its product offering into top-performing international and global equity strategies, as with its Emerging Markets Stars business, with appeal in the institutional as well as wholesale channels, particularly in North America.

 

Gavin Rochussen, CEO, Polar Capital said:

"The establishment of Phaeacian Partners is the next step in Polar's strategy to build out our international and global products and our institutional presence in North America.

 

"The strategies that Pierre and Greg will manage for us, as well as their investment philosophy, are a natural fit with Polar Capital's investment-led approach to managing our clients' money. We will provide Phaeacian with a best-in-class operational structure, allowing them the investment autonomy to build on their impressive track record and proven, repeatable investment process. They are an excellent addition to Polar Capital, and I am looking forward to working with them."

 

Pierre Py and Greg Herr said:

"We are thoroughly looking forward to working with Polar Capital. The partnership allows us to focus on generating exceptional, investment-led returns for our clients, while benefiting from the outstanding business support Polar Capital can provide. It is an ideal fit for us in terms of operating environment and culture."

 

*Source: Morningstar as at 30 September 2020. FPA International Value is in the Morningstar Foreign Small/Mid Blend Morningstar category and FPA Paramount in the Morningstar World Large Stock category.

For further information please contact:

Polar Capital + 44 (0)20 7227 2700

Gavin Rochussen (Chief Executive)

John Mansell (Executive Director)

Samir Ayub (Finance Director)

 

Numis Securities Limited - Nomad and Joint Broker + 44 (0) 20 7260 1000

Charles Farquhar

Stephen Westgate

Kevin Cruickshank (QE)

 

Peel Hunt LLP - Joint Broker +44 (0)20 7418 8893

Andrew Buchanan

Rishi Shah

 

Camarco +44 (0)20 3757 4984

Ed Gascoigne-Pees

Georgia Edmonds

Monique Perks

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRBUBDGGXBDGGL
Date   Source Headline
17th Apr 20243:55 pmRNSDirector/PDMR Shareholding
12th Apr 20245:43 pmRNSHolding(s) in Company
11th Apr 20247:00 amRNSAuM Update
9th Apr 20244:01 pmRNSChange of Company Secretary
15th Mar 20243:02 pmRNSForm 8.3 - Renalytix PLC
15th Mar 202410:23 amRNSForm 8.3 - Renalytix PLC - Replacement
13th Mar 20246:14 pmRNSForm 8.3 - RENALYTIX PLC
7th Mar 20244:30 pmRNSHolding(s) in Company
6th Mar 20245:47 pmRNSForm 8.3 - DIRECT LINE INSURANCE GROUP PLC
6th Mar 20245:37 pmRNSForm 8.3 - RENALYTIX PLC
27th Feb 20242:19 pmRNSForm 8.3 - Wincanton PLC
7th Feb 20242:09 pmRNSDirector/PDMR Shareholding
1st Feb 20247:00 amRNSBlock listing Interim Review
25th Jan 20244:53 pmRNSForm 8.3 -Wincanton PLC
11th Jan 20247:00 amRNSAuM Update
10th Jan 20242:54 pmRNSHolding(s) in Company
10th Jan 20242:51 pmRNSHolding(s) in Company
20th Nov 20237:00 amRNSPolar Capital Holdings Unaudited interim results
9th Nov 20237:00 amRNSInvestor Presentation covering Interim Results
26th Oct 20237:00 amRNSNotice of Interim Results
12th Oct 20237:00 amRNSAuM Update
28th Sep 20235:36 pmRNSResult of AGM
18th Aug 20234:45 pmRNSDirector/PDMR Shareholding
1st Aug 202312:05 pmRNSBlock listing Interim Review
19th Jul 20234:34 pmRNSDirector/PDMR Shareholding
18th Jul 20234:30 pmRNSDirector/PDMR Shareholding
13th Jul 202311:01 amRNSDirector/PDMR Shareholding - Replacement
13th Jul 202310:48 amRNSDirector/PDMR Shareholding
13th Jul 202310:31 amRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSAuM Update
26th Jun 20233:34 pmRNSInvestor Presentation covering Full Year Results
26th Jun 20237:00 amRNSGroup Audited Results for year ended 31 March 2023
1st Jun 20237:00 amRNSTotal Voting Rights
25th May 202312:26 pmRNSIssue of Equity
10th May 20233:10 pmRNSDirector/PDMR Shareholding
21st Apr 20232:36 pmRNSHolding(s) in Company
14th Apr 20234:01 pmRNSDirector/PDMR Shareholding
13th Apr 20237:00 amRNSAuM Update
31st Mar 202312:23 pmRNSDirector/PDMR Shareholding
10th Mar 20233:17 pmRNSDirector/PDMR Shareholding
24th Feb 20235:18 pmRNSForm 8.3 - REDX Pharma PLC
16th Feb 20235:06 pmRNSDirector/PDMR Shareholding
7th Feb 202311:09 amRNSHolding(s) in Company
1st Feb 20237:00 amRNSBlock listing Interim Review
12th Jan 20237:00 amRNSAuM Update
30th Dec 20227:00 amRNSDirectorate Change
21st Nov 20227:00 amRNSUnaudited interim results
15th Nov 20227:00 amRNSInvestor Presentation covering Interim Results
24th Oct 20227:00 amRNSNotice of Results
19th Oct 20222:52 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.